Werewolf Therapeutics, Inc. Stock Price, News & Analysis

Werewolf Therapeutics, Inc. (Nasdaq: HOWL), based in Cambridge, Massachusetts, will present at the H. C. Wainwright 23rd Annual Global Investment Conference on September 13-15, 2021. CEO Daniel J. Hicklin, Ph.D. will provide a company overview available on-demand starting September 13 at 7:00 am EDT, archived for 90 days. Werewolf specializes in developing conditionally activated therapeutics to enhance the immune system's response to cancer, leveraging its innovative PREDATOR™ platform and its lead candidates, WTX-124 and WTX-330, for solid tumors.

Werewolf Therapeutics has announced a clinical trial collaboration with Merck to evaluate WTX-124, a conditionally activated Interleukin-2 molecule, alongside KEYTRUDA® in treating solid tumors.

This trial will assess the safety and efficacy of WTX-124 both alone and in combination with KEYTRUDA. Werewolf plans to submit an IND application to the FDA in 2022, aiming to start Phase 1 trials if approved. WTX-124 is designed to enhance treatment while minimizing toxicity, potentially improving options for cancer patients.

Werewolf Therapeutics (Nasdaq: HOWL) announced its financial results for Q2 2021. The company raised approximately $109.2 million through its IPO in May, boosting cash reserves to $183.2 million. R&D expenses rose to $7.3 million from $3.8 million year-over-year, while general and administrative costs increased to $3.7 million from $1.3 million. The net loss for Q2 stood at $10.9 million compared to $2.3 million the previous year. Werewolf aims to file INDs for its INDUKINE™ products, WTX-124 and WTX-330, and was recently added to the Russell 2000 Index.

Werewolf Therapeutics will be added to the Russell 2000® Index on June 28, 2021, a significant milestone reflecting its progress in developing cancer therapeutics.

The company is advancing its lead programs, WTX-124 and WTX-330, into clinical trials. The Russell 2000® Index is a key benchmark representing the small-cap segment of the U.S. equity market, used by many institutional investors for index funds.

Approximately $10.6 trillion in assets benchmark against Russell's indexes, underlining the importance of this inclusion for Werewolf Therapeutics.

Werewolf Therapeutics, Inc. (NASDAQ: HOWL) has appointed Chulani Karunatilake, Ph.D., as the new Chief Technology Officer (CTO). With over 30 years of experience in Chemistry and Manufacturing Controls (CMC), Dr. Karunatilake will oversee manufacturing operations as the company advances its lead therapeutic programs, WTX-124 and WTX-330, which are designed to treat cancer. His prior experience includes roles at Maverick Therapeutics and Nektar Therapeutics, emphasizing drug development and regulatory management. This appointment aims to enhance Werewolf's capabilities in immuno-oncology.

Werewolf Therapeutics (NASDAQ: HOWL) has successfully completed its initial public offering, raising $120 million in gross proceeds.

For Q1 2021, the company reported a net loss of $7.4 million, an increase from $3.8 million in Q1 2020. Cash and cash equivalents declined to $84.6 million compared to $92.6 million at the end of 2020.

Research and development expenses surged to $4.8 million, up from $2.8 million in the same quarter of 2020, reflecting the ongoing development of its lead cancer treatment programs.

Werewolf Therapeutics (NASDAQ: HOWL) appointed Mike Sherman, CEO of Chimerix, Inc., to its board of directors, enhancing the company's leadership during a critical growth phase. Sherman brings over 30 years of experience in biotechnology, including a successful tenure at Endocyte, where he led a $2.1 billion acquisition by Novartis. His expertise in corporate strategy and product focus will support Werewolf's advancements in its innovative cancer therapies, notably the WTX-124 and WTX-330 candidates, which are progressing towards clinical development.

Werewolf Therapeutics, a biopharmaceutical company listed on Nasdaq as HOWL, announced that its CEO, Daniel J. Hicklin, Ph.D., will present at the Jefferies Virtual Healthcare Conference on June 3rd at 11 am ET. The company focuses on engineering conditionally activated therapeutics to enhance the immune system for cancer treatment. Their proprietary PREDATOR™ platform aims to create molecules that activate specifically in the tumor microenvironment. WTX-124 and WTX-330 are two leading candidates currently in preclinical studies.

Werewolf Therapeutics, Inc. (NASDAQ: HOWL) announced the pricing of its upsized initial public offering (IPO) of 7,500,000 shares at $16.00 each, yielding approximately $120 million in gross proceeds. An option for underwriters to purchase an additional 1,125,000 shares is also granted. Trading on the Nasdaq Global Select Market begins on April 30, 2021, with the offering closing anticipated on May 4, 2021. The company focuses on developing immunotherapeutics for cancer treatment, leveraging its PREDATOR™ platform.